Mahnoor Zafarullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mahnoor Zafarullah has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Harb
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
1 shared publication Ayesha Imran Butt
Allama Iqbal Medical College, Lahore, Pakistan
1 shared publication- Hafsa Arshad Azam Raja
Rawalpindi Medical University, Rawalpindi, Pakistan
1 shared publication Ikram Ul Haq Chaudhry
Muzaffarabad General Hospital, Muzaffarabad, AJK, Pakistan
1 shared publicationImad Akbar
Massachusetts General Hospital, Boston, USA
1 shared publicationMahum Mujtaba
Shifa College of Medicine, Islamabad, Pakistan
1 shared publication
Latest Publications
- 10 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 769
Clinical, Laboratory and Radiological Factors associated with posterior reversible encephalopathy syndrome (PRES) in patients with eclampsia or pre-eclampsia: a systematic review and meta-analysis
Background Posterior reversible encephalopathy syndrome (PRES) remains a serious neurological complication associated with eclampsia/pre-eclampsia. Early identification remains challenging due to heterogeneous presentations and limited consensus on associated clinical and laboratory factors. Therefore, we aimed to assess clinical and laboratory factors associated with PRES by pooling data from primary studies. Methods A systematic review was conducted following PRISMA 2020 guidelines. PubMed, Embase, and Web of science were searched from inception to March 25, 2025. Primary outcomes included PRES incidence, while secondary outcomes included biomarkers, maternal and fetal outcomes, and imaging characteristics. Risk of bias was assessed using Newcastle Ottawa’s scale and National Institutes of Health (NIH) tool. A random-effects model was employed for meta-analysis. Results A total of 28 studies were included. The pooled incidence of PRES was 38.68% (95% CI: 29.63–48.59), with significant heterogeneity (I²=98.5%). Patients with PRES had significantly higher liver enzymes (ALT: MD 35.88 IU/L; AST: MD 48.69 IU/L) and lower platelet counts (MD: −31.15 × 10⁹/L). Total bilirubin was also elevated. Maternal mortality risk was increased but not statistically significant (RR: 4.06), while stillbirth and preterm birth showed no significant associations. Imaging findings commonly involved the frontal (43.05%) and temporal lobes (20.33%). Conclusion PRES is a frequent complication of pre-eclampsia and eclampsia, with identifiable clinical and biochemical factors associated with its occurrence, particularly elevated liver enzymes and thrombocytopenia. Despite substantial heterogeneity, these findings may help inform clinical assessment, especially in resource-limited settings. Further high-quality prospective studies are needed to develop standardized predictive models and improve early detection.
- 10 September 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (10) , 769
Clinical, Laboratory and Radiological Factors associated with posterior reversible encephalopathy syndrome (PRES) in patients with eclampsia or pre-eclampsia: a systematic review and meta-analysis
Background Posterior reversible encephalopathy syndrome (PRES) remains a serious neurological complication associated with eclampsia/pre-eclampsia. Early identification remains challenging due to heterogeneous presentations and limited consensus on associated clinical and laboratory factors. Therefore, we aimed to assess clinical and laboratory factors associated with PRES by pooling data from primary studies. Methods A systematic review was conducted following PRISMA 2020 guidelines. PubMed, Embase, and Web of science were searched from inception to March 25, 2025. Primary outcomes included PRES incidence, while secondary outcomes included biomarkers, maternal and fetal outcomes, and imaging characteristics. Risk of bias was assessed using Newcastle Ottawa’s scale and National Institutes of Health (NIH) tool. A random-effects model was employed for meta-analysis. Results A total of 28 studies were included. The pooled incidence of PRES was 38.68% (95% CI: 29.63–48.59), with significant heterogeneity (I²=98.5%). Patients with PRES had significantly higher liver enzymes (ALT: MD 35.88 IU/L; AST: MD 48.69 IU/L) and lower platelet counts (MD: −31.15 × 10⁹/L). Total bilirubin was also elevated. Maternal mortality risk was increased but not statistically significant (RR: 4.06), while stillbirth and preterm birth showed no significant associations. Imaging findings commonly involved the frontal (43.05%) and temporal lobes (20.33%). Conclusion PRES is a frequent complication of pre-eclampsia and eclampsia, with identifiable clinical and biochemical factors associated with its occurrence, particularly elevated liver enzymes and thrombocytopenia. Despite substantial heterogeneity, these findings may help inform clinical assessment, especially in resource-limited settings. Further high-quality prospective studies are needed to develop standardized predictive models and improve early detection.
- Open Access
- 21 June 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
Precision neuroprotection in cardiac surgery: a structured narrative review of multimodal, data-driven perioperative care
Neurological injury remains a major contributor to morbidity, mortality, and long-term cognitive decline in patients undergoing cardiac surgery, despite significant advancements in surgical techniques and cardiopulmonary bypass (CPB) technology. These injuries arise from a complex interplay of embolic load, hypoperfusion, impaired cerebral autoregulation, inflammatory responses, and patient-specific vulnerabilities, underscoring the need for a precision-based approach rather than generalized neuroprotective strategies. This narrative review synthesizes current evidence across the perioperative continuum to propose an integrated, data-driven framework for precision neuroprotection. This structured narrative review was conducted according to the SANRA framework. Literature was retrieved from PubMed and Scopus databases covering publications from January 2005 to October 2025.Preoperative risk assessment is enhanced by multimodal imaging, frailty evaluation, neurocognitive screening, metabolic and inflammatory biomarkers, and emerging machine learning models capable of predicting postoperative delirium and cognitive dysfunction. Intraoperatively, precision neuroprotection centers on autoregulation-guided blood pressure management, individualized perfusion targets during CPB, optimized temperature and glucose control, and multimodal neuromonitoring, including transcranial Doppler (TCD), near-infrared spectroscopy (NIRS), processed EEG/BIS, and embolic load characterization, to identify and mitigate cerebral insults in real time. Postoperative precision strategies incorporate biomarker-based surveillance, delirium screening, early mobilization, cognitive rehabilitation, and digital monitoring through wearable devices and remote platforms to detect delayed neurological decline. Although these modalities demonstrate clear potential, major research gaps persist, including variability in device accuracy, limited ability to differentiate embolic subtypes, inconsistent biomarker performance and insufficient integration of AI-driven analytics with clinical workflows. Collectively, available evidence supports the transition from fragmented, organ-focused neuroprotection to a unified, multimodal continuum that leverages data integration, personalized thresholds, and predictive analytics. Future large-scale, human-centered clinical trials are essential to validate this approach and operationalize precision neuroprotection across cardiac surgical practice.
- 21 June 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
Open AccessPrecision neuroprotection in cardiac surgery: a structured narrative review of multimodal, data-driven perioperative care
Neurological injury remains a major contributor to morbidity, mortality, and long-term cognitive decline in patients undergoing cardiac surgery, despite significant advancements in surgical techniques and cardiopulmonary bypass (CPB) technology. These injuries arise from a complex interplay of embolic load, hypoperfusion, impaired cerebral autoregulation, inflammatory responses, and patient-specific vulnerabilities, underscoring the need for a precision-based approach rather than generalized neuroprotective strategies. This narrative review synthesizes current evidence across the perioperative continuum to propose an integrated, data-driven framework for precision neuroprotection. This structured narrative review was conducted according to the SANRA framework. Literature was retrieved from PubMed and Scopus databases covering publications from January 2005 to October 2025.Preoperative risk assessment is enhanced by multimodal imaging, frailty evaluation, neurocognitive screening, metabolic and inflammatory biomarkers, and emerging machine learning models capable of predicting postoperative delirium and cognitive dysfunction. Intraoperatively, precision neuroprotection centers on autoregulation-guided blood pressure management, individualized perfusion targets during CPB, optimized temperature and glucose control, and multimodal neuromonitoring, including transcranial Doppler (TCD), near-infrared spectroscopy (NIRS), processed EEG/BIS, and embolic load characterization, to identify and mitigate cerebral insults in real time. Postoperative precision strategies incorporate biomarker-based surveillance, delirium screening, early mobilization, cognitive rehabilitation, and digital monitoring through wearable devices and remote platforms to detect delayed neurological decline. Although these modalities demonstrate clear potential, major research gaps persist, including variability in device accuracy, limited ability to differentiate embolic subtypes, inconsistent biomarker performance and insufficient integration of AI-driven analytics with clinical workflows. Collectively, available evidence supports the transition from fragmented, organ-focused neuroprotection to a unified, multimodal continuum that leverages data integration, personalized thresholds, and predictive analytics. Future large-scale, human-centered clinical trials are essential to validate this approach and operationalize precision neuroprotection across cardiac surgical practice.